182 related articles for article (PubMed ID: 23211868)
1. Halting metastasis through CXCR4 inhibition.
Ramsey DM; McAlpine SR
Bioorg Med Chem Lett; 2013 Jan; 23(1):20-5. PubMed ID: 23211868
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
3. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
4. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
Khan A; Greenman J; Archibald SJ
Curr Med Chem; 2007; 14(21):2257-77. PubMed ID: 17896975
[TBL] [Abstract][Full Text] [Related]
5. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.
Otsuka S; Bebb G
J Thorac Oncol; 2008 Dec; 3(12):1379-83. PubMed ID: 19057260
[TBL] [Abstract][Full Text] [Related]
6. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
Fierro FA; Brenner S; Oelschlaegel U; Jacobi A; Knoth H; Ehninger G; Illmer T; Bornhäuser M
Leukemia; 2009 Feb; 23(2):393-6. PubMed ID: 18615106
[No Abstract] [Full Text] [Related]
7. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 receptor as a promising target for oncolytic drugs.
Lavrovsky Y; Ivanenkov YA; Balakin KV; Medvedeva DA; Ivachtchenko AV
Mini Rev Med Chem; 2008 Oct; 8(11):1075-87. PubMed ID: 18855724
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
10. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
11. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
12. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
13. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Duda DG; Kozin SV; Kirkpatrick ND; Xu L; Fukumura D; Jain RK
Clin Cancer Res; 2011 Apr; 17(8):2074-80. PubMed ID: 21349998
[TBL] [Abstract][Full Text] [Related]
14. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
16. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.
Xue LJ; Mao XB; Ren LL; Chu XY
Cancer Med; 2017 Jun; 6(6):1424-1436. PubMed ID: 28544785
[TBL] [Abstract][Full Text] [Related]
18. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
19. The role of CXCL12 in tumor microenvironment.
Meng W; Xue S; Chen Y
Gene; 2018 Jan; 641():105-110. PubMed ID: 29017963
[TBL] [Abstract][Full Text] [Related]
20. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
